Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Homatropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.95 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.95 |
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 0.95 |
| ▸ | CHRM5 known ✓ | P08912 | 5/20 | 0.95 |
| ▸ | CHRM4 known ✓ | P08173 | 4/20 | 0.95 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.68 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.68 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.68 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.68 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.68 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.62 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.62 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.62 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.62 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.62 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.62 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.55 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.55 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.55 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Homatropine SCHEMBL220965 | 1.00 | LMNA (0.97) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL23969 | 0.99 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL9653008 | 0.99 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL15275620 | 0.99 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL23970 | 0.99 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL23468168 | 0.99 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL41951 | 0.97 | CHRM2 (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL41950 | 0.97 | CHRM2 (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL658437 | 0.96 | LMNA (0.95) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL14672464 | 0.96 | LMNA (0.95) | LMNACYP2D6CYP2C9HSD17B10CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | ELIXIR MEDICAL CORPORATION (US) | 2018-11-13 | — | — | US | claimed |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2017-05-04 | — | — | US | claimed |
| CN-105380947-A | Macrolide compound and use method thereof | ELIXIR MEDICAL CORP | 2016-03-09 | — | — | CN | claimed |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2015-12-10 | — | — | US | claimed |
| US-20130230571-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2013-09-05 | — | — | US | claimed |
| EP-2624834-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | Elixir Medical Corporation (US) | 2013-08-14 | — | — | EP | claimed |
| EP-1480677-B8 | COMPOSITION FOR STABILIZING HYALURONIC ACID | CARL ZEISS MEDITEC SAS (FR) | 2012-05-23 | — | — | EP | claimed |
| WO-2012047813-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2012-04-12 | — | — | WO | claimed |
| EP-1480677-B1 | COMPOSITION FOR STABILIZING HYALURONIC ACID | IOLTECH (FR) | 2012-02-29 | — | — | EP | claimed |
| US-8088789-B2 | Administering hemiketal ring and seco-macrocyclic lactones; immunosuppressive, anti-proliferative, anti-fungal and anti-tumor | ELIXIR MEDICAL CORPORATION (US) | 2012-01-03 | — | — | US | claimed |
| EP-0652774-B1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | PROCTER & GAMBLE (US) | 1997-05-07 | — | — | EP | claimed |
| US-5614178-A | TRANSDERMAL | THE PROCTER & GAMBLE COMPANY (US) | 1997-03-25 | — | — | US | claimed |
| EP-0652774-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER. | PROCTER & GAMBLE (US) | 1995-05-17 | — | — | EP | claimed |
| CN-1091317-A | Improve the part input of medicine | PROCTER & GAMBLE (US) | 1994-08-31 | — | — | CN | claimed |
| EP-0608320-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| CN-1072863-A | Be used to improve the dermal osmosis system of the reinforcement of medicine localized delivery | RICHARDSON VICKS INC (US) | 1993-06-09 | — | — | CN | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | CHRM2, CHRM1, CHRM5 | CHRM2 1/4885CHRM1 2/4885CHRM3 4/4885 |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | CHRM2 1/4885CHRM1 2/4885CHRM3 5/4885 |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | CHRM2 1/4885CHRM1 2/4885CHRM3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.